Programme

This is a Provisional Conference Programme.

For further information on this event please contact us.

‘Welcome Talk:
MODERN VACCINES, ADJUVANTS & DELIVERY SYSTEMS – An Overview’
Denis Christensen
(CRODA Denmark, Denmark)

‘Keynote Talk:
Title to be confirmed’
Peter L. Andersen
(Novo Nordisk Foundation, Copenhagen, Denmark)

‘Securing the supply chain for vaccine adjuvants in the future’
Denis Christensen
(CRODA Denmark, Denmark)

‘What will the next generation of adjuvants look like?‘
Derek O’Hagan
(GSK, Cambridge, Massachusetts, USA)

‘Improved adjuvants and delivery systems: A public health imperative’
Martin Friede
(WHO, Geneva, Switzerland)

‘Deep learning of vaccine adjuvant by machine and immunology’
Ken Ishii
(IMS/University of Tokyo, Tokyo, Japan)

‘Pre-clinical optimization of adjuvant formulation, route, and regimen of SARS-SoV-2 subunit vaccine’
Will Lykins
(AAHI, Access to Advanced Health Institute, Seattle, Washington, USA)

‘Cationic liposome-based adjuvants for transmission-blocking vaccines against SARS-CoV-2’
Gabriel Pedersen
(Statens Serum Institut, Copenhagen, Denmark)

‘Transdifferentiating Th17 cells to a non-IL-17 expressing phenotype using liposomal adjuvants’
Katharina Wørzner
(Statens Serum Institut, Copenhagen, Denmark)

‘The influence of spray drying carriers on powder properties of dried CAF04 liposomes’
Anitta Lutta
(Statens Serum Institut, Copenhagen, Denmark)

‘scRNA-seq analysis identifies early transcriptional differences in the draining lymph node between different adjuvant systems’
Julie Zimmermann
(Statens Serum Institut, Copenhagen, Denmark)

‘New adjuvant formulation in clinical development for CAF10b’
Rasmus Mortensen
(Statens Serum Institut, Copenhagen, Denmark)

‘Natural QS21: Approved, Abundant and Available’
Damian Hiley
(Desert King International, San Diego, California, USA)

‘LNPs for mRNA vaccines’
Speaker to be confirmed

‘Title to be confirmed’
Matthew Heath
(Allergy Therapeutics (UK) Ltd, Worthing, West Sussex, UK)

‘Vaccination against peanut-allergy’
Martin Bachmann
(Inselspital , Berne, Switzerland)

‘Title to be confirmed on Saponins and/or Alum adjuvants’
Laurent Duroux
(CRODA Denmark, Denmark)

‘Matrix-M adjuvant: A key component in several novel vaccine candidates’
Linda Stertman
(Novavax AB, Uppsala, Sweden)

‘The role of interferons and inflammasomes in adjuvant induced cellular immunity’
Ed Lavelle
(Trinity College Dublin, Dublin, Ireland)

‘Immunogenicity of adjuvanted plant-produced SARS-CoV-2 Beta Spike VLP vaccine in New Zealand white rabbits’
Martha M. O’Kennedy¹, Celia Abolnik², Tanja Smith², Thopisang Motlou^3,4, Kruger Goosen⁵, Kamogelo M. Sepotokele², Robyn Roth¹, Ilse du Preez¹, Alma Truyts¹, Hester C Stark², Martin Magwaza⁶, Osborn Mahanjana⁷, Jan A. Verschoor⁸, Penny L. Moore^3,4 and Yolandy Lemmer¹
( ¹ Council for Scientific and Industrial Research (CSIR) Next Generation Health, Pretoria, South Africa. ² Department of Production Animal Studies, Faculty of Veterinary Science, University of Pretoria (UP), South Africa. ³ SA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa. ⁴ National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa. ⁵ La-Bio Research Animal Laboratory (a Division of Disease Control Africa), 33 Eland Street, Koedoespoort Industrial, Pretoria, SA. ⁶ Tautomer Pty Ltd., 260 Cradock Avenue, Lyttelton Manor, Centurion, 0157. ⁷ 3Sixty Biopharmaceuticals Pty Ltd., 23 Impala Road, Block B, Chislehurston, Sandton, Gauteng, 2196. ⁸ Emeritus Professor and consultant, Department of Biochemistry, Genetics and Microbiology, University of Pretoria, South Africa.)

‘Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR-/- mice’
Martha M. O’Kennedy¹, Peter Coetzee², Otto Koekemoer², Lissinda du Plessis³, Carina Lourens⁴, Lusisizwe Kwezi⁵, Ilse du Preez¹, Sipho Mamputha¹, Daria A. Rutkowska¹, Jan A. Verschoor⁶ and Yolandy Lemmer¹
( ¹ Council for Scientific and Industrial Research (CSIR) Next Generation Health, Pretoria, South Africa. ² Onderstepoort Biological Products SOC Ltd, Onderstepoort, South Africa. ³ Centre of Excellence for Pharmaceutical Sciences (PharmacenTM), North-West University, Potchefstroom, South Africa. ⁴ Department of Veterinary Tropical Diseases, University of Pretoria, Onderstepoort, South Africa. ⁵ Council for Scientific and Industrial Research (CSIR) Chemical cluster, Pretoria, South Africa. ⁶ Emeritus Professor and consultant, Department of Biochemistry, University of Pretoria}

‘Title to be confirmed’
Jean Haensler
(Sanofi Pasteur, Lyon, France)

‘An adjuvant platform based on TMV spherical particles: An overview’
Yuri Vasiliev
(Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia)

‘Title to be confirmed’
Stefan Jungbluth
(EUVaccine Initiative, Heidelberg, Germany)

Special Session:
Immune profiling of adjuvanted vaccines
Moderator: Arnaud Didier-Laurent
(University of Geneva, Geneva, Switzerland)

This provisional programme is correct at the time of publication. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the conference programme.